A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK-Reference-Cited by-同舟云学术

A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK

Published:2021-10-03 Issue:10 Volume:20 Page:1311-1325
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Vyse Andrew¹,Campling James¹,Czudek Carole¹,Ellsbury Gillian¹,Mendes Diana²,Reinert Ralf-Rene³,Slack Mary⁴

Affiliation:

1. Medical Affairs, Pfizer Ltd, Walton Oaks, Tadworth, KT20 7NS, UK

2. Health & Value, Pfizer Ltd, Walton Oaks, Tadworth, KT20 7NS, UK

3. Medical Affairs, Pfizer Inc, Paris, France

4. School of Medicine & Dentistry, Griffith University, Gold Coast Campus, Queensland 4222, Australia

Funder

Pfizer UK

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2021.1984888

Reference124 articles.

1. Outbreaks of severe pneumococcal disease in closed settings in the conjugate vaccines era, 2010–2018: A systematic review to inform national guidance in the UK

2. Risk factor profiles and clinical outcomes for children and adults with pneumococcal infections in Singapore: A need to expand vaccination policy?

3. A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large cps Fragment from an Oral Streptococcus

4. Pneumonia in the immunocompetent patient

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom;Expert Review of Vaccines;2023-09-11

2. A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult;Frontiers in Public Health;2023-06-29

3. Invasive pneumococcal surveillance to assess the potential benefits of extended spectrum conjugate vaccines (PCV15/PCV20) in older adults;Epidemiology and Infection;2023

4. Evolution of Pneumococcal Vaccine Recommendations and Criteria for Decision Making in 5 Western European Countries and the United States;MDM Policy & Practice;2023-01

5. Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease;Expert Review of Pharmacoeconomics & Outcomes Research;2022-11-03